Background: Although there are limited data on oxycodone overdose, it has been suggested
Introduction:
Oxycodone hydrochloride is a mu opioid receptor agonist commonly used for moderate to severe pain and available in immediate and sustained release forms 1 . It is a semi-synthetic form of morphine with similar properties causing analgesia and euphoria and thus also has abuse potential 2 . Unlike morphine it has a high oral bioavailability and a longer half-life of around 2 to 5.5 hours, making it a good choice for difficult to control pain 3 . There are limited data on oxycodone's effects in overdose, isolated to a few case-studies and post-mortem analyses 2, 4-11 . As with other opioid overdoses, effects in overdose include central nervous system depression, respiratory depression, coma and death 9 . In Australia oxycodone is only available under prescription with restricted benefit 12 . Sustained release (SR) oxycodone (OxyContin ® ) has been available in Australia since 1999, under the same restriction 13 .
Evidence supports the use of oxycodone over codeine and oral morphine in the context of chronic pain and it is becoming increasingly recommended in a number of pain control guidelines [14] [15] [16] . Reports show increased prescribing and increased black market demand for oxycodone with increasing intravenous use and overdose presentations within Australia and other countries 2, [17] [18] [19] .
Given the high prescription rate and increasing use of oxycodone, an understanding of its effects and treatment in overdose is necessary. In addition, a recent report from poison centres in seven countries showed an increasing number of oxycodone exposures in all countries, including the United States, Australia and Europe. 20 It has been suggested that oxycodone may cause QT prolongation, and therefore increase the risk of torsades des pointes (TdP) 4, 21 . The availability of a sustained release formulation of oxycodone means that there will be delayed and prolonged opioid effects in overdose potentially requiring a longer length of stay and increased use of critical care resources.
This study aimed to investigate the clinical features, electrocardiogram (ECG) parameters, particularly QT interval, and the treatment requirements for oxycodone in overdose.
Methods:
The study was a retrospective review of oxycodone overdoses taken from clinical database which prospectively records information on all patients admitted to a toxicology service. The use of the database and patient information has previously been granted exemption as an audit by the Institutional Ethics Committee.
The study was undertaken in a large regional toxicology unit which is the primary referral centre for over 500,000 people. All presentations are either seen and reviewed in the Emergency Department, or admitted as in-patients under the toxicology service. Clinical information for all toxicology presentations is collected prospectively on a clinical data collection form at the time of presentation and entered into a relational database by two trained personnel blinded to any study hypotheses.
All presentations to the toxicology service between January 2001 and May 2011 were reviewed and admissions which included immediate and/or sustained release oxycodone were extracted. Oxycodone ingestion was based on patient history taken at multiple time points and collateral history from other sources such as family and ambulance services. for the same period were extracted from the database (Figure 1 ).
Patients qualified for ICU admission if they required ongoing airway support (intubation and ventilation), a decreased level of consciousness (GCS < 9), inotropic support (haemodynamic monitoring) or multi-organ failure. Discharge was determined by criteria pre-defined by the toxicology service, in conjunction with the psychiatry team and could occur 24 hours a day.
The following outcomes were used to assess the severity of overdose: a decreased level of consciousness defined as a GCS < 9; an abnormal QT defined as the QT-HR pair being above the abnormal line on the QT nomogram; the requirement for naloxone and the use of a naloxone infusion; and the hospital length of stay (LOS).
Medians and interquartile ranges (IQR) are reported for all continuous variables and 95%
confidence intervals (CI) are reported for major dichotomous outcomes. The 95% CIs are calculated using the Wilson's procedure with a continuity correction. 23 Statistical and graphical analyses were done in GraphPad Prism version 5.03 for Windows, GraphPad
Software, San Diego California USA, www.graphpad.com.
Results:
There were 140 oxycodone overdose presentations in 121 patients, of which three presentations were excluded as they were per rectum or intravenous recreational overdoses, 
Neurological effects:
Sixty five (47%) patients had a GCS of less than 15 at first contact with emergency medical services (EMS), of which 33 had ingested IR oxycodone, 22 had ingested SR oxycodone and GCS between 14 and 9 and twenty nine (21%) had a GCS less than 9. Figure 2 shows the relationship between increasing oxycodone dose and reduced GCS on initial contact.
Cardiovascular effects:
One hundred and thirty six presentations had a documented BP and HR. The median minimum systolic BP was 104 mmHg (IQR: 96-118 mmHg; range: 60-160 mmHg) and eleven (8%) patients had an episode of hypotension. Only three had a systolic BP less than 80 mmHg (60, 69 and 74 mmHg). The first was a beta-blocker overdose requiring intubation and high dose insulin and glucose as an inotrope, the second had ingested 60 mg oxycodone IR and the third had taken a large overdose including 1600 mg IR oxycodone, 100 mg diazepam, 2400 mg ibuprofen and 5000 mg doxylamine. 58-190 mg) which was the same as patients with a normal QT-HR pair (100 mg, IQR: 50-300 mg). Sixteen of the 20 patients with an abnormal QT had an ECG done prior to discharge (2) or on a previous or subsequent admission (14) which was normal in all cases.
Naloxone
Naloxone boluses were administered in 65 admissions (47%) and 33 (24%) of these were then continued on a naloxone infusion. Nine patients were treated with IM naloxone prehospital, 38 received IV naloxone pre-hospital, with a total of forty five (35%) presentations receiving either IM and/or IV naloxone pre hospital. Seven patients required intubation, of which only one patient did not receive a bolus of naloxone prior to intubation. This patient had co-ingested amitriptyline. Activated charcoal was only administered in four patients.
Discussion:
This study shows that oxycodone overdose results in significant central nervous system (CNS) depression in the majority of patients. Bradycardia appeared to be a feature of oxycodone overdose with almost a fifth of patients having a HR less than 60 bpm. An abnormal QT interval occurred in a similar number of patients where an ECG was available, suggesting that oxycodone may be a risk factor for TdP. In this study only a small proportion of patients were intubated and ventilated which is most likely due to the use of bolus naloxone and naloxone infusions. Patients requiring naloxone had a longer LOS but could be managed in a high dependency setting rather than requiring mechanical ventilation.
The majority of patients who presented had taken an overdose of their own prescribed oxycodone with suicidal intent. One third had taken a slow release preparation and since regular use confers a level of tolerance to oxycodone this may explain why only half had an altered GCS on first presentation to emergency services. Nevertheless, initial GCS was associated with the dose ingested, with higher doses resulting in a lower GCS (Figure 2 ).
Almost half the presentations required naloxone at some point during their presentation, usually pre-hospital, and a quarter required a naloxone infusion, matching the pattern of initially altered GCS and SR overdose presentation numbers. Ingestions of SR oxycodone were associated with greater reductions in GCS and increased naloxone use, in keeping with its longer duration of action.
The requirement for naloxone is an important clinical indicator, due to the increased LOS and resource burden it entails. Although naloxone is highly effective at reversing opioid toxicity, it is ineffective at reversing other CNS depressants such as benzodiazepines, which were commonly co-ingested. It is also difficult to manage naloxone infusions in patients with chronic pain. Patients on infusions require higher level nursing care and a high dependency setting. However, mechanical ventilation and ICU admission are a greater burden on resources. Less than 10% of presentations in our study required intubation and mechanical ventilation. The LOS of oxycodone presentations is not significantly different to the general LOS of all toxicology patients, unless associated with the need for naloxone either as a bolus or infusion (Figure 4 ).
Recent literature had suggested a relationship between oxycodone and prolonged QT 4, 21 .
Fanoe et al 21 found a relationship between prolonged QTc and increasing oxycodone doses in a study of 27 patients and showed that oxycodone inhibited HERG channels expressed in HEK293 cells. Using the QT nomogram 22 and manually measured QT intervals we found 20
(17%) QT-HR pairs above the nomogram line. The majority of these patients had a HR over 100 bpm, whereas we found overall a greater association with bradycardia in oxycodone overdoses. This may suggest it is a combination of medications, e.g., oxycodone and quetiapine (with its anticholinergic effect producing a tachycardia) that places the patient at risk of an abnormal QT-HR pair. This association with a prolonged QT in therapeutic doses 21 and now in overdose supports oxycodone as an agent that prolongs the QT. However, the risk of TdP and other arrhythmias remains unclear. These have not been reported in the literature and it is well recognised that some drugs can prolong the QT without an associated risk of demonstrates that at least in this study there has been a reduction in overdoses of morphine and methadone, and oxycodone is the predominant opioid overdose.
There are a number of limitations with this study, including the method of data collection and the non-randomised retrospective nature of the sample. However, all the data collected from toxicology patients and entered into the database is done prospectively and independent of any study hypothesis. Detailed information on naloxone treatment was obtained from the medical record using a clinical research form but was not blinded. This is unlikely to have introduced any bias because the use, dose and frequency of naloxone are recorded on the medication chart for all patients.
Oxycodone overdose was not confirmed with drug concentrations and dose was estimated based on patient history. However, further collateral history was collected from ambulance and relatives when available, including empty ingested drug packets. Previous studies in this population of patients 24, 25 have shown that a combination of patient history and collateral information are a good estimate of the true ingested dose. There may be an element of selection bias because patients presented to a single tertiary referral toxicology unit.
However, the unit services a large surrounding area and is the only admitting hospital for all toxicology patients.
A limitation of the ECG analysis was the timing of the ECG which was not the same for every patient. The large catchment area and distances involved meant that patients presenting may have been stabilised in other centres or presented some hours after their ingestion, delaying the recording of an ECG.
In the majority of presentations co-ingestants had been taken which may confound the study, especially with QT prolongation. However, none of the co-ingestants in the patients with prolonged QT have been shown to cause QT prolongation. In one patient who ingested a tricyclic antidepressant there was a prolonged QT because the QRS was widened (Figure 3 ).
Another potential bias was the assessment of the requirement for naloxone. There are no definitive criteria for the selection of patients who received naloxone, and the use of an initial bolus of naloxone was dictated by either the pre-hospital emergency services or the emergency department doctor. The use of naloxone infusions was always discussed with the attending toxicologist. Although there was always a preference for the use of naloxone rather than intubation and mechanical ventilation, some patients were intubated prior to establishing the diagnosis of opioid overdose. Intubation and mechanical ventilation is likely to be associated with a longer LOS than a naloxone and was associated with a longer LOS in this study.
This study has shown that in addition to the expected CNS depression, the opioid oxycodone patients only given a bolus dose of naloxone and patients given a naloxone infusion.
